News Sentiment

RGEN sentiment intelligence

Repligen Corporation news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 54 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Instruments & Supplies Read-through group
Latest close 144.24 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+1.3% over one week, +10.5% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Repligen (RGEN) Stock May Trade At Fair Value But At A Sales Premium

Market Reaction

Balanced read

63/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction 1.3% Price digesting
Trend fit Trend inactive 10.5% over four weeks
Fair value -2.3% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 33
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
TradingView 11
Market source 11
Stock Titan 6
simplywall.st 4
GuruFocus 3
AD HOC NEWS 2
Moomoo 2
Quiver Quantitative 2

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 18
Analyst action 3
Guidance 2
Balance sheet 1
Macro sensitivity 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-54 of 54
Investing.com Nigeria Direct company coverage

Form 144 REPLIGEN CORP For: 25 June By Investing.com

This article announces the filing of Form 144 for Repligen Corp (RGEN) on June 25. Form 144 indicates an intent to sell restricted securities. The brief notice provides the company name, the form type, and the date of the filing.

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 18:40
Source
Investing.com Nigeria
Stock Titan Direct company coverage

[144] REPLIGEN CORP SEC Filing

This article reports on a Form 144 SEC filing by Repligen Corp (RGEN). The filing indicates a proposed sale of 733 shares of common stock with an aggregate market value of $106,285, acquired through restricted stock vesting on November 18, 2024. The filing was accepted by SEC EDG

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 17:40
Source
Stock Titan
GuruFocus Direct company coverage

Repligen Corp (RGEN) Shares Fall 4.1% -- What GF Score of 83 Tells Investors

Repligen Corp (RGEN) shares fell 4.1% on June 22, 2026, dropping to $126.67. Despite this, the stock is considered 28.0% undervalued according to its GF Value™ of $175.89, and holds a strong GF Score™ of 83/100, primarily due to high growth potential. However, recent insider sell

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 00:39
Source
GuruFocus
DirectorsTalk Interviews Direct company coverage

Repligen Corporation (RGEN) Stock Analysis: Assessing a 33% Upside Potential in Bioprocessing Innovation

Repligen Corporation (RGEN) is a significant player in the bioprocessing sector within the healthcare industry, with a market capitalization of $7.45 billion. Analysts are optimistic, projecting a 33.39% upside potential from its current trading price of $132.02, supported by str

Tone
Positive 73/100
Event
Market update
Published
22 Jun 2026 14:12
Source
DirectorsTalk Interviews
AD HOC NEWS Direct company coverage

Repligen Stock - Long-term strategy and bioprocessing niche

This article focuses on Repligen (US7607591002), a specialized life-science tools provider, and its long-term strategy in the bioprocessing market. It highlights the company's business model, which centers on supplying technologies for biologic drug manufacturing, positioning it

Tone
Positive 71/100
Event
Market update
Published
20 Jun 2026 18:39
Source
AD HOC NEWS
Insider Monkey Direct company coverage

Repligen Corporation (RGEN) Slid on Softened Enthusiasm for Life Sciences Tools

Osterweis Capital Management's Q1 2026 investor update highlighted Repligen Corporation (NASDAQ: RGEN), noting its underperformance due to a general softening in enthusiasm for life sciences tools. Despite this, the fund remains positive about Repligen, citing its lack of exposur

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 08:48
Source
Insider Monkey